Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

The European Medicines Agency’s human medicines committee has recommended that BeOne Medicines’ Tevimbra (tislelizumab) be ...

But while an improved reputation can be a by-product of patient engagement, it should not be the driving force behind it.

Biogen’s Qalsody (tofersen) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first ...

Rezpegaldesleukin, which has already been granted FDA fast track designation for moderate-to-severe atopic dermatitis, is ...

Inclusion isn’t just about eligibility; it’s about participation Trials often demand time, travel and flexibility, resources ...

Discover how patient-centred design transforms inclusive clinical trials. Learn to overcome trial recruitment challenges by ...

Clinical trial patient recruitment and retention practices have significantly advanced over the last 15 years thanks to ...

Artificial intelligence (AI) in clinical research has the potential to accelerate patient access to new treatments by ...

So far this year, we have witnessed several announcements that could have a major impact on the clinical trials market and ...

Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat newly diagnosed multiple myeloma ...

Eli Lilly’s Alzheimer’s disease (AD) drug donanemab has been recommended by the European Medicines Agency’s human medicines ...